BioCentury | Mar 1, 2019
Financial News

Sage raises $575M in follow-on

Weeks ahead of the PDUFA date for its antidepressant Zulresso brexanolone, Sage Therapeutics Inc. (NASDAQ:SAGE) raised $575 million in a follow-on. Including an overallotment priced Wednesday, the company sold 3.8 million shares at $150, a...
BioCentury | Sep 21, 2018
Clinical News

Progenics' prostate cancer imaging agent meets specificity endpoint in Phase III

...Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said SPECT/CT imaging with its 99mTc-MIP-1404 (1404, F-1311) imaging agent met the...
...95% CI to exceed 60%. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), New York, N.Y. Product: 99mTc-MIP-1404 (1404, F-1311...
...Sensitivity and specificity; safety Status: Phase III data Milestone: NA Jaime De Leon 99mTc-MIP-1404, trofolastat (1404, 99mtc-trofolostat, f-1311) Progenics...
BioCentury | Jul 17, 2018
Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

Cellectar Biosciences Inc. (NASDAQ:CLRB) said a patient with advanced Waldenström's macroglobulinemia receiving CLR 131 in a Phase II trial achieved a 94% reduction in tumor burden and complete resolution in four of five targeted tumor...
BioCentury | Aug 18, 2017
Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

Cellectar Biosciences Inc. (NASDAQ:CLRB) reported additional data from the first cohort of a Phase I trial in about 33 patients with relapsed or refractory multiple myeloma (MM) showing that a single dose of 12.5 mCi/m...
BioCentury | Apr 4, 2017
Clinical News

CLR 131: Ph II started

Cellectar began an open-label, U.S. Phase II trial to evaluate a single dose of 25 mCi/m 2 IV CLR 131 plus once-weekly oral dexamethasone for up to 12 weeks in about 80 patients with hematologic...
BioCentury | Jan 12, 2017
Clinical News

99mTc-MIP-1404: Ph III ongoing

...open-label, North American Phase III proSPECT-AS trial evaluating a single 20 mCi IV injection of 99mTc-MIP-1404...
...for active surveillance. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), New York, N.Y. Product: 99mTc-MIP-1404 (1404, F-1311) (formerly 99mTc-trofolostat...
...cancer Endpoint: Specificity and sensitivity compared to histopathology; safety Status: Phase III ongoing Milestone: NA Alicia Parker 1404 99mTc-MIP-1404 F-1311 Progenics...
BioCentury | Oct 24, 2016
Clinical News

CLR 131: Additional Phase I data

Data from 4 evaluable patients with relapsed or refractory MM in the second cohort of an open-label, dose-escalation, U.S. Phase I trial showed that a single 18.75 mCi/m2 dose of IV CLR 131 with or...
BioCentury | Jan 25, 2016
Clinical News

CLR 131: Interim Phase I data

Interim data from 5 patients with relapsed or refractory MM in the first cohort of an open-label, dose-escalation, U.S. Phase I trial showed that a single dose of 12.5 mCi/m 2 IV CLR 131 led...
BioCentury | Jan 18, 2016
Clinical News

99mTc-MIP-1404: Phase III started

...North American Phase III proSPECT-AS trial to evaluate a single 20 mCi IV injection of 99mTc-MIP-1404...
...surveillance, but are planning to undergo radical prostatectomy. Within 3-6 hours of dosing with the 1404...
...will be taken. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Product: 99mTc-MIP-1404 (1404, F-1311 ) (formerly 99mTc-trofolostat...
BioCentury | Oct 2, 2015
Financial News

Edge, Mirna price IPOs

Edge Therapeutics Inc. (NASDAQ:EDGE) and Mirna Therapeutics Inc. (NASDAQ:MIRN) each began trading Thursday after pricing IPOs. Edge gained $1.94 (18%) to $12.94 after it raised $80.5 million through the sale of 7.3 million shares at...
Items per page:
1 - 10 of 136